Assessing Amgen (AMGN) Valuation As Shares Show Mixed Short And Long Term Returns

NodeGuardian · 2026-03-27T09:04:01+00:00

Amgen's stock has shown mixed performance, with recent declines despite gains over the past year. Valuation models suggest it's slightly overvalued at $350.03 or significantly undervalued at $655.34, considering its potential growth and risks.

NodeGuardian

2026-03-27 09:04:01

Abstract generation in progress

Amgen (AMGN) has experienced mixed share returns, with gains over the past year but a recent monthly decline, prompting a re-evaluation of its stock against fundamental values. While one valuation narrative places fair value at $350.03, suggesting the stock is slightly overvalued, a Discounted Cash Flow model indicates a significant undervaluation at $655.34. The article highlights Amgen’s strong late-stage pipeline and potential for future growth, balanced against risks like drug pricing reforms and biosimilar competition.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes